Pharmanovia announced the expansion of its neurology portfolio through a new licensing agreement with U.S.-based biopharmaceutical company Axsome Therapeutics. "The agreement gives Pharmanovia the exclusive marketing rights to Sunosi, a first in class medicine used to improve wakefulness and reduce excessive daytime sleepiness in adults with narcolepsy or obstructive sleep apnoea, in Europe and MENA regions. Pharmanovia will continue researching solriamfetol’s potential in children. A pivotal Phase III study and longer-term extension study, exploring the safety and effectiveness of solriamfetol in children with narcolepsy, will be initiated by Pharmanovia, with the aim of bringing this breakthrough therapy to young people affected by this debilitating disease. The agreement also allows Pharmanovia to explore solriamfetol’s potential in other neurological conditions, such as attention deficit hyperactivity disorder, or ADHD," the company stated.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on AXSM:
- Axsome Therapeutics enters license agreement with Pharmanovia
- Axsome Therapeutics Enters into License Agreement with Pharmanovia to Expand Commercialization and Further Develop Sunosi® (solriamfetol) in Europe
- Axsome facing Auvelity IP challenge ‘not a surprise,’ says BofA
- Axsome received Paragraph IV certification notice on Auvelity ANDA from Teva
- Axsome Therapeutics management to meet with Truist